Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SIBIA Neurosciences (SIBI) -- Ignore unavailable to you. Want to Upgrade?

To: lrb who wrote (361)	5/26/1999 7:04:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 579

Larry: I hope that Mr. Keane is saying that the deal is for research relating to 3182 and subsequent molecules, and that, as an aside, Lilly gets the option. Hope won't buy you a cup of coffee, so I'd email and ask him personally. I'm going to, as soon as I can catch my balance. SIBI has always said that they would license all of their molecules. They go out of their way in the 10-K, etc., to say that they intend to partner everything. So, it seems, to me, that Mr. Keane is merely talking the company talk. I like that. These guys are throwbacks. - g - They could give us a feel for the depth of the relationship with Lilly. We have been led to believe, in the distant past, that there was active and ongoing efforts at Lilly with VGCC screening. That's documented somewhere back in this thread. We also know that SIBI was excited about their independent VGCC program with pain, and that this research was "pulled back" from Lilly in the last renewal of the long-terminated agreement. And now Lilly is back, but not in VGCCs. The question is, have they been hanging around all the time? If so, this is the way I read this interesting agreement........ Lilly just took a right to first refusal to buy SIBI. If any of the three phase II trials are promising, it's an expensive buy. If that royalty ass'd with the option is high, I really like this deal. Cash was running short, and the trials are not sufficiently powered, IMO. This keeps that broad pipeline viable, and we need to remember..... the 1553A and 1508Y data isn't far off. Now, the question of the day..... if I'm correct, then who the heck was selling 200K shares today? That doesn't fit. Another missing piece..... VGCC/pain. We have seen BVF lighten up, when they apparently had to do such, by dribbling into demand. I get the idea that they are doing their best not to hurt companies that they still like, while recouping some needed cash. Maybe it was them? Lost, I'm lost! With everyone busy studying SUGN-like innovation in funding, I hope that the option is loaded in SIBI's favor. However, I don't have any reason to regard 1508Y or 1553A as anything other than interesting crap shoots. I had that attitude even before the latest SNAP/NRGN "encounters". So....... leaving fantasyland.......